Leaflet: information for the user
Vardenafil hydrochloride 5 mg film-coated tablets
Vardenafil
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What Vardenafil Pensa is and what it is used for
2. What you need to know before you take Vardenafil Pensa
3. How to take Vardenafil Pensa
4. Possible side effects
5. Storage of Vardenafil Pensa
6. Contents of the pack and additional information
This medicationcontains vardenafilo, an active ingredient from the group of medications known as phosphodiesterase type 5 inhibitors, which are used to treat erectile dysfunction in adult men, a condition that consists of difficulty in achieving or maintaining an erection.
At least one in every ten men has, at some point, problems achieving or maintaining an erection. This may be due to physical or psychological causes, or a combination of both. Regardless of the cause, muscle and blood vessel alterations result in insufficient blood in the penis to achieve and maintain an erection.
Vardenafilo will only act when you are sexually stimulated. This medication reduces the action of a natural substance in the body that prevents an erection. Vardenafilo allows for an erection with a sufficient duration to maintain a satisfactory sexual relationship.
Do not take Vardenafilo
- If you are allergic to vardenafilo or any of the other components of this medication (listed in section 6). Signs of an allergic reaction include skin rash, itching, swelling on the face or lips, and difficulty breathing.
- If you are taking medications that contain nitrates, such as glyceryl trinitrate for angina, or that release nitric oxide, such as amyl nitrite. Taking these medications together with vardenafilo may severely affect your blood pressure.
- If you are taking ritonavir or indinavir, medications for the treatment of human immunodeficiency virus (HIV) infections.
- If you have a severe heart or liver problem.
- If you are undergoing renal dialysis.
- If you have recently experienced a cerebral ischemic accident or a heart attack.
- If you have low blood pressure, or if you have had it in the past.
- If you have a family history of degenerative eye diseases (such as retinitis pigmentosa).
- If you have ever experienced vision loss due to a lack of blood supply to the optic nerve, known as nonarteritic anterior ischemic optic neuropathy (NAION).
- If you are taking riociguat. This medication is used to treat pulmonary hypertension (high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (high blood pressure in the lungs caused by clots). PDE5 inhibitors, such as vardenafilo, have shown to increase the hypotensive effect of this medication. If you are taking riociguat or are unsure, consult your doctor.
- If you have ever developed a severe skin rash or skin peeling, blisters, and/or mouth sores after taking vardenafilo.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Be especially careful with vardenafilo
- If you have heart problems, as having sex may pose a risk to you.
- If you have irregular heartbeats (cardiac arrhythmia) or any inherited heart disease that alters your electrocardiogram.
- If you have any physical condition that affects the shape of your penis. For example, angulation, Peyronie's disease, or cavernous fibrosis.
- If you have a disease that may cause erections that do not subside (priapism). For example, sickle cell anemia, multiple myeloma, and leukemia.
- If you have a stomach ulcer (also known as a gastric or peptic ulcer).
- If you have bleeding disorders (such as hemophilia).
- If you are using any other treatment for erectile dysfunction, including vardenafilo film-coated tablets (see the section: "Use of Vardenafilo with other medications").
- If you experience sudden vision loss or distortion, or if your vision becomes darker while taking vardenafilo, stop taking vardenafilo and contact your doctor immediately.
- Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with vardenafilo treatment. Discontinue vardenafilo treatment and seek medical attention immediately if you experience any of the symptoms related to these severe skin reactions described in section 4.
Children and adolescents
Vardenafilo should not be used in children or adolescents under 18 years old.
Other medications and Vardenafilo
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication, including those purchased without a prescription.
Some medications may cause problems, especially the following:
- Nitrates, medications for angina or that release nitric oxide, such as amyl nitrite. Taking these medications together with vardenafilo may severely affect your blood pressure. Do not take vardenafilo without consulting your doctor first.
- Medications for the treatment of cardiac arrhythmias, such as quinidine, procainamide, amiodarone, or sotalol.
- Ritonavir or indinavir, medications for HIV infections. Do not take vardenafilo without consulting your doctor first.
- Ketoconazole or itraconazole, antifungal medications.
- Erythromycin or clarithromycin, macrolide antibiotics.
- Alpha-blockers, a group of medications used to treat high blood pressure and enlarged prostate (such as benign prostatic hyperplasia).
- Riociguat.
Do not use vardenafilo film-coated tablets in combination with another medication for erectile dysfunction, including vardenafilo buccal dispersible tablets.
Taking Vardenafilo with food, drinks, and alcohol
- You can take vardenafilo with or without food, but it is recommended not to do so after a large or high-fat meal, as the effect may be delayed.
- Do not drink grapefruit juice while taking vardenafilo, as it may interfere with the normal effect of the medication.
- Drinking alcoholic beverages may worsen erectile dysfunction.
Pregnancy and breastfeeding
Vardenafilo should not be used in women.
Driving and operating machinery
In some people, vardenafilo may cause dizziness or affect vision. Do not drive or operate tools or machinery if you feel dizzy or have vision problems after taking vardenafilo.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is 10 mg.
Take a vardenafilo tablet 25 to 60 minutes before sexual activity. With sexual stimulation, you can obtain an erection from 25 minutes to four or five hours after taking vardenafilo.
- Swallow the tablet with a glass of water.
Do not take vardenafilo film-coated tablets with any other vardenafilo formulation.
Do not take vardenafilo more than once a day.
If you estimate that the action of vardenafilo is too strong or weak, inform your doctor. He or she may suggest a change to another vardenafilo formulation with a different dose based on the effect it has on you.
If you take more Vardenafilo than you should
Taking too many vardenafilo tablets can cause more side effects and produce intense back pain.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, vardenafil may cause side effects, although not everyone will experience them. Most of these side effects are mild or moderate.
Some patients have experienced a decrease or partial loss of vision, distorted, blurred, or dim central vision, suddenly, temporarily, or permanently, in one or both eyes. Stop taking vardenafil and contact your doctor immediately.
There have also been reported cases of sudden hearing loss.
There have been reported cases of sudden death, rapid or irregular heartbeats, heart attacks, chest pain, and cerebral circulation problems (including temporary reduction of blood flow to parts of the brain and cerebral hemorrhage), in men taking vardenafil. Most men who have experienced these side effects had pre-existing heart problems before taking this medication. It is not possible to determine if these events were directly related to vardenafil.
The possibility of presenting an adverse effect is described using the following categories:
Frequent adverse effects:can affect more than 1 in 10 people:
- Headache.
Common adverse effects:can affect up to 1 in 10 people:
- Dizziness.
- Facial flushing.
- Nasal congestion or rhinorrhea.
- Indigestion.
Uncommon adverse effects:can affect up to 1 in 100 people:
- Swelling of the skin and mucous membranes, including facial, lip, or throat swelling.
- Sleep disturbances.
- Numbness and altered tactile perception.
- Somnolence.
- Visual effects; eye hemorrhage, visual color effects, eye pain, and photosensitivity.
- Tinnitus; vertigo.
- Rapid or irregular pulse.
- Difficulty breathing.
- Nasal congestion.
- Reflux, gastritis, abdominal pain, diarrhea, vomiting, nausea, and dry mouth.(Nausea),dry mouth.
- Elevated liver enzymes in the blood.
- Skin rashes, red skin.
- Back pain or muscle pain; elevated creatine phosphokinase enzyme in the blood; muscle rigidity.
- Prolonged erection.
- General malaise.
Rare adverse effects:can affect up to 1 in 1,000 people:
-Eye inflammation(conjunctivitis).
- Allergic reaction.
- Anxiety.
- Syncope.
- Amnesia (memory loss).
- Convulsions.
- Glaucoma (increased intraocular pressure), watery eyes.
- Effects on the heart (such as myocardial infarction, tachycardia, or angina).
- High or low blood pressure.
- Nasal bleeding.
- Alterations in liver function test results in the blood.
- Sensitivity to sunlight.
- Painful erection.
- Chest pain.
- Temporary reduction of blood flow to parts of the brain.
Very rare or unknown frequency adverse effects:can affect fewer than 1 in 10,000 people or the frequency cannot be estimated from available data:
- Blood in urine (hematuria).
- Penile bleeding (hemorrhage).
- Presence of blood in semen (hematospermia).
- Sudden death.
- Cerebral hemorrhage.
- Reddish, non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers in the mouth, throat, nose, genitals, and eyes. These severe skin eruptions can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
- Distorted, blurred, or dim central vision or sudden vision loss.
Reporting adverse effects
If you experience any type of adverse effect, consult your doctor, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Tablet core: microcrystalline cellulose, crospovidone, anhydrous colloidal silica, magnesium stearate.
Coating: hypromellose, titanium dioxide (E171), macrogol 400, yellow iron oxide (E172), red iron oxide (E172).
Appearance of the product and contents of the packaging
Vardenafilo Pensa 5 mg are film-coated tablets of orange color, cylindrical and biconvex, engraved with the logo “VR5”.
Each package contains 4 or 20 tablets. Some package sizes may only be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Towa Pharmaceutical, S.A.
C/ de Sant Martí, 75-97
08107 Martorelles (Barcelona)
Spain
Responsible for manufacturing
Laboratorios Cinfa, S.A.
Olaz-Chipi, 10 Polígono Industrial Areta
31620 Huarte – Pamplona (Navarra)
Spain
Last review date of this leaflet:February 2025
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.